Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events

Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation

“…For example, imaging manifestations, like hyperprogression and pseudoprogression, could display a false signal, leading to a significant delay in the treatment plan. 30 To address the above issues, nanomedicines have garnered increasing interest for cancer radio-immunotherapy due to their improved pharmacokinetics and incredible auxiliary functions (Fig. 1).…”

“…For example, imaging manifestations, like hyperprogression and pseudoprogression, could display a false signal, leading to a significant delay in the treatment plan. 30…”

18F-FDG PET/CT in the clinical-diagnostic workup of patients treated with immunotherapy: when and how?

“…For the above reasons, efforts have been made to find response criteria specifically adapted for immunotherapy for both CT (irRC, irRECIST, iRECIST, imRECIST) [5] and PET/CT, namely PET Response Evaluation Criteria for Immunotherapy (PERCIMT) [6], PET/CT Criteria for early prediction of Response to Immune checkpoint inhibitor therapy (PECRIT) [7], Immunotherapy-modified PERCIST (imPERCIST) [8] and immune PET Response Criteria in Solid Tumors (iPERCIST) [9] (Table 1). These criteria were developed based on melanoma (PERCIMT, imPERCIST and PECRIT) and lung cancer (iPERCIST), the two solid tumors in which more experience has been reported on the clinical use of PET in immunotherapy.…”